Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL10964286 | 0.97 | CYP3A4 (0.47) | CYP3A4CYP2D6CYP2C19LTA4HTOP2A | |
| Phosphoric Acid SCHEMBL5804027 | 0.95 | CYP3A4 (0.46) | CYP3A4CYP2D6CYP2C19LTA4HTOP2A | |
| SCHEMBL10963902 | 0.93 | CA12 (0.46) | CYP3A4CYP2D6CYP2C19ALDH1A1MMP8 | |
| SCHEMBL361963 | 0.86 | MAPT (0.43) | CYP2C19ALDH1A1 | |
| SCHEMBL10266709 | 0.84 | SMN1; SMN2 (0.50) | ALDH1A1MMP8 | |
| SCHEMBL11494074 | 0.84 | MMP8 (0.53) | ALDH1A1MMP8 | |
| SCHEMBL10258404 | 0.83 | CYP3A4 (0.49) | CYP3A4CYP2D6CYP2C19LTA4HTOP2A | |
| SCHEMBL7288615 | 0.81 | MMP8 (0.49) | CYP3A4CYP2D6CYP2C19ALDH1A1MMP8 | |
| SCHEMBL3998475 | 0.81 | SLC6A3 (0.44) | ALDH1A1 | |
| SCHEMBL1916468 | 0.80 | SMN1; SMN2 (0.58) | MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-8710061-B2 | Compounds for the reduction of β-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710061-B2 | Compounds for the reduction of β-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| EP-1553084-A1 | PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-0034647-B1 | 4-ARYLOXY-3-PHENYLPIPERIDINE DERIVATIVES, INTERMEDIATES, A PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS AND THEIR USE AS MEDICAMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-06-05 | — | — | EP | disclosed |
| US-4424357-A | Process for preparing 4-aryloxy-3-phenylpiperidines | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1984-01-03 | — | — | US | disclosed |
| EP-0014997-B1 | 4-ARYLOXY- AND 4-ARYLTHIO-3-PHENYLPIPERIDINE DERIVATIVES, A PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-07-20 | — | — | EP | disclosed |
| US-4382141-A | ANTIDEPRESSANTS, ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1983-05-03 | — | — | US | disclosed |
| US-4312876-A | CENTRAL NERVOUS SYSTEM | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1982-01-26 | — | — | US | disclosed |
| US-4302590-A | THE 4-HYDROXY DERIVATIVE; ANALGESICS, ANTIDEPRESSANTS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1981-11-24 | — | — | US | disclosed |
| EP-0034647-A2 | 4-Aryloxy-3-phenylpiperidine derivatives, intermediates, a process for the preparation of such compounds and their use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-09-02 | — | — | EP | disclosed |
| EP-0014997-A1 | 4-Aryloxy- and 4-arylthio-3-phenylpiperidine derivatives, a process for the preparation of such compounds and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-09-03 | — | — | EP | disclosed |
| US-4216218-A | Antidepressant and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines | AMERICAN HOECHST CORPORATION (US) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | CYP3A4 2737/4885CYP2D6 3158/4885CYP2C19 4099/4885 |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | CYP3A4 2737/4885CYP2D6 3158/4885CYP2C19 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.